Page URL: https://www.bionews.org.uk/page_142572

Gene therapy successfully treats 'bubble boy' disease

29 April 2019
Appeared in BioNews 996

Infants born with a severe immunodeficiency disorder have been successfully treated in a new gene therapy trial. 

Seven of the eight children in the trial with X-linked severe combined immunodeficiency (SCID-X1) – often dubbed 'bubble boy' disease – now have a full immune system.

'These patients are toddlers now, who are responding to vaccinations and have immune systems to make all immune cells they need for protection from infections as they explore the world and live normal lives,' said first author of the study Dr Ewelina Mamcarz at the St Jude Children's Research Hospital in Memphis, Tennessee.

'This is a first for patients with SCID-X1,' she added. The results were published in The New England Journal of Medicine.

The children were born with a mutation in the gene, Il2RG, necessary for correct immune system development. The gene therapy used an engineered virus to replace the faulty gene with a functional copy. 

The seven children are now producing functional cells that constitute a full immune system, including T cells, natural killer cells, and B cells.

SCID-X1 and similar disorders are often called 'bubble-boy' diseases, owing to the plastic enclosures that were commonly used to protect children with the disorder from possible infections. Because they lack a proper immune system, contact with the outside world poses a major infection risk, and even a common cold can be fatal. The disease predominantly affects boys.

Until now, the best treatment had been a bone-marrow transplant from a donor-matched sibling. However, this option is available to less than 20 percent of patients. 

Consequently, efforts have focused on trying to deliver a functional copy of the gene to children who are unable to receive a transplant. 

Approaches to engineer a suitable virus that was capable of replacing the mutated gene had mixed results: prior studies reported improved immune response but caused leukaemia in some patients (see BioNews 439). 

In this latest trial, researchers used a non-infectious, disabled relative of the HIV virus to replace the faulty gene in the cells that make up the immune system. In addition, they treated patients with a low dose of chemotherapy prior to treatment, in order to optimise growth of the new, functional stem cells in the bone marrow. 

The children involved in the study have no signs of leukaemia up to two years after their treatment. 

While continual monitoring of the children is required to verify the long-term outcome, the results from the trial are a first, and the researchers hope a similar approach could be used to treat other disorders such as sickle cell disease. 

'From a physiological point of view and from a quality-of-life point of view, this is a cure,' Dr James Downing, president of St. Jude Children's Research Hospital told Nature News. 'Will it be a durable cure? Only time will tell.' 

SOURCES & REFERENCES
Babies with 'bubble boy disease' cured using gene therapy developed by St Jude's
NBC News |  17 April 2019
Experimental gene therapy frees 'bubble-boy' babies from a life of isolation
Nature News |  17 April 2019
Lentiviral Gene Therapy Combined with Low-Dose Busulfan in Infants with SCID-X1
New England Journal of Medicine |  18 April 2019
St Jude gene therapy cures babies with 'bubble boy' disease
St Jude's Children's Research Hospital |  17 April 2019
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
28 October 2019 - by Dr Rosie Gilchrist 
The Bill and Melinda Gates Foundation has teamed up with the National Institutes of Health (NIH), the US national science funding body, to pledge US$100 million each over four years towards development of gene therapies for HIV and sickle cell anaemia...
30 October 2017 - by Jen Willows 
NICE has approved a gene therapy for children with a rare disorder that leaves them with no functioning immune system...
13 October 2014 - by Dr James Heather 
Gene therapy to treat children with 'bubble boy syndrome' seems to be both safe and effective, a study published in the New England Journal of Medicine has found...
7 January 2008 - by Stuart Scott 
A boy enrolled on a pioneering gene therapy trial has developed leukaemia, his doctors based at London's Great Ormond Street Hospital have announced. The three-year-old was of one of 10 patients treated for X-SCID: a genetic disorder whereby a mutation in the IL2RG gene leaves carriers without...
7 March 2005 - by BioNews 
The US Food and Drug Administration (FDA) has recommended that gene therapy treatments for an inherited immune disorder are limited to those who have no alternative. The move follows news that a third child in a similar French trial has developed leukaemia. The trial for X-linked severe combined immunodeficiency disorder...
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.